Investors & Media

Transformative science, targeted medicines

Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4 Statement of changes in beneficial ownership of securities View HTML
0000899243-17-005572.pdf
0000899243-17-005572.rtf
0000899243-17-005572.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-17-002766.pdf
0001179110-17-002766.rtf
0001179110-17-002766.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-17-002767.pdf
0001179110-17-002767.rtf
0001179110-17-002767.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-17-002768.pdf
0001179110-17-002768.rtf
0001179110-17-002768.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-17-002769.pdf
0001179110-17-002769.rtf
0001179110-17-002769.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-17-002770.pdf
0001179110-17-002770.rtf
0001179110-17-002770.xls
SC 13G/A An amendment to the SC 13G filing View HTML
0001193805-17-000188.pdf
0001193805-17-000188.rtf
0001193805-17-000188.xls
SC 13G/A An amendment to the SC 13G filing View HTML
0000315066-17-001482.pdf
0000315066-17-001482.rtf
SC 13G/A An amendment to the SC 13G filing View HTML
0000921895-17-000347.pdf
0000921895-17-000347.rtf
SC 13G/A An amendment to the SC 13G filing View HTML
0001144204-17-008995.pdf
0001144204-17-008995.rtf
0001144204-17-008995.xls